NON SMALL CELL LUNG CANCER(NSCLC) WITH ACTIVATING EGFR MUTATION IN CHILE

被引：0
|
作者：
Aren, Osvaldo [1 ]
Voge, Conrado [2 ]
Orellana, Eric [3 ]
Kleinmann, Sergio [2 ]
Fica, Mauricio
Cerda, Humberto [1 ]
Suarez, Claudio
机构：
[1] Inst Nacl Canc, Med Oncol Serv, Santiago, Chile
[2] Clin Alemana, Med Oncol Serv, Santiago, Chile
[3] Clin Santa Maria, Med Oncol Serv, Valparaiso, Chile
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; exon 19 deletion and exon 21 L858R mutation; EGFR mutation; Chile;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1515 / S1515
页数：1
相关论文
共 50 条
  • [1] EGFR mutation in non-small cell lung cancer(NSCLC) in South Croatia
    Mladinov, Suzana
    Skopljanac, Ivan
    Ivcevic, Veljka
    Kuret, Sendi
    Durdov, Meri Glavina
    Mise, Kornelija
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [2] EGFR mutation and response to chemotherapy in non-small-cell lung cancer (NSCLC) patients.
    Lee, KH
    Han, SW
    Jeong, S
    Kim, DW
    Chung, DH
    Im, SA
    Kim, TY
    Heo, DS
    Bang, YJ
    Kim, NK
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 641S - 641S
  • [3] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
    Paulina Bracht, Jillian Wilhelmina
    Karachaliou, Niki
    Berenguer, Jordi
    Pedraz-Valdunciel, Carlos
    Filipska, Martyna
    Codony-Servat, Carles
    Codony-Servat, Jordi
    Rosell, Rafael
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
  • [4] Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
    Shuhang Wang
    Xiaomei Su
    Hua Bai
    Jun Zhao
    Jianchun Duan
    Tongtong An
    Minglei Zhuo
    Zhijie Wang
    Meina Wu
    Zhenxiang Li
    Jian Zhu
    Jie Wang
    [J]. Journal of Hematology & Oncology, 8
  • [5] Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
    Wang, Shuhang
    Su, Xiaomei
    Bai, Hua
    Zhao, Jun
    Duan, Jianchun
    An, Tongtong
    Zhuo, Minglei
    Wang, Zhijie
    Wu, Meina
    Li, Zhenxiang
    Zhu, Jian
    Wang, Jie
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [6] Efficacy and safety study of osimertinib in advanced non-small cell lung cancer (NSCLC) with EGFR mutation
    Garcia Samblas, Victoria
    Fernandez Madrigal, Laura
    Rodriguez Garces, Maria Yeray
    Inoriza, Angel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] EGFR mutation and management of advanced non-small cell lung cancer (NSCLC) adenocarcinoma in Germany and France
    Souquet, P. J.
    Dietel, M.
    Eberhardt, W.
    Fournel, P.
    Von der Schulenburg, J. M. Graf
    Locher, C.
    Sabourin, J. C.
    Schirmacher, P.
    Thomas, M.
    Schuette, W.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S817 - S817
  • [8] EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data
    Dulloo, Sean
    Almusarhed, Manar
    Chen, Ryan
    Akala, Oyeyemi
    Varadhan, Balaji
    Chauhan, Meera
    Ahmed, Samreen
    [J]. LUNG CANCER, 2021, 156 : S40 - S40
  • [9] Evaluation of EGFR mutation testing in plasma from non-small cell lung cancer (NSCLC) patients
    Gonzalez De Aledo-Castillo, J. M.
    Victoria, I.
    Arcocha, A.
    Reguart, N.
    Molina Porto, R.
    Puig-Butille, J. A.
    [J]. CLINICA CHIMICA ACTA, 2019, 493 : S570 - S570
  • [10] Nivolumab in non-small-cell lung cancer with EGFR mutation
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Yasuda, Y.
    Funazo, T.
    Hirai, T.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (03) : 777 - 778
12345